secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001558370-24-014262
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M
-----------------------------------------------------------------------

- Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).
- GAAP net loss narrowed to $21.4M ($0.39 loss per share) from $30.4M ($0.63) in Q3 2023.
- Non-GAAP net loss $15.2M ($0.28 per share) vs $24.2M ($0.50) prior year.
- Raised FY2024 net sales guidance to $377M-$379M from prior $370M-$376M.
- Gross margin ~77%, non-GAAP ~82%; ended quarter with $267.2M cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024014262/0001558370-24-014262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024014262/gkos-20241104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer